Minetta Liu

Minetta Liu has been a leader in integrating ctDNA monitoring into clinical trials as a real-time endpoint for therapy assessment, demonstrating that serial ctDNA measurements during neoadjuvant and adjuvant breast cancer treatment provide earlier and more granular response information than standard imaging and pathological assessments. Her clinical research at Mayo Clinic has established ctDNA dynamics as prognostic and potentially predictive biomarkers that can guide treatment duration and intensity decisions. Her work is accelerating the clinical adoption of ctDNA monitoring as a standard component of breast cancer treatment management.